1-2 of 2
Remie Houston
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Jak2 V617F Reversible Activation Shows an Essential Requirement for Jak2 V617F in Myeloproliferative Neoplasms (MPNs)

Andrew Dunbar, Robert L. Bowman, Young Park, Franco Izzo, Robert M. Myers, Abdul Karzai, Won Jun Kim, Inés Fernández Maestre, Michael R. Waarts, Abbas Nazir, Wenbin Xiao, Max Brodsky, Mirko Farina, Louise Cai, Sheng F Cai, Benjamin Wang, Wenbin An, Julie Yang, Shoron Mowla, Shira E. Eisman, Tanmay Mishra, Remie Houston, Emily Guzzardi, Anthony R. Martinez Benitez, Aaron D Viny, Richard Koche, Dan A. Landau, Ross L. Levine
Journal: Blood
Blood (2022) 140 (Supplement 1): 803–804.
https://doi.org/10.1182/blood-2022-164827
Published: 2022
Journal Articles

The Second Generation Type II JAK2 Inhibitor, AJ1-10502, Demonstrates Enhanced Selectivity, Improved Therapeutic Efficacy and Reduced Mutant Cell Fraction Compared to Type I JAK2 Inhibitors in Models of Myeloproliferative Neoplasms (MPNs)

Shivam Rai, Jan Stetka, MARC Usart, Hui Hao-Shen, Young Park, Remie Houston, Anthony R. Martinez Benitez, Matthew Wereski, Emily Guzzardi, Sonali Persaud, Hailey Ramzan, Alan Futran, Charley Xu, Jeremy Greenwood, Sayan Mondal, Craig Masse, Ross L. Levine, Radek C. Skoda, Andrew Dunbar
Journal: Blood
Blood (2022) 140 (Supplement 1): 6722–6723.
https://doi.org/10.1182/blood-2022-162621
Published: 2022